Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer

Not Applicable

• Conditions: Thrombosis
• Interventions: Diagnostic Test: Genetic Mutations

• Registration Number: NCT03180567
• Lead Sponsor: Tanta University

Brief Summary

As drug response is a complex trait in the majority of cases using an optimal starting dose for an individual may reduce the time taken to reach a stable INR, and reduce the risk of having either a high INR (with a risk of bleeding) or a low INR (with a risk of thrombosis)

Detailed Description

The results of this project will benefit in (1) Identification of novel features or mutation types in warfarin resistance genomes. (2) To determine whether other polymorphisms in noncoding regions or their unique haplotype combinations contribute to the variability in the maintenance dose of warfarin, and (3)personalization of the drug and deciding the correct dose from the start.

Study Timeline

• Status Verified: 2017-06
• Study Start: 2017-06-06
• Study First Submitted: 2017-06-06
• Study First Submitted QC: 2017-06-06
• Last Update Submitted: 2017-06-06
• Study First Posted: 2017-06-08
• Last Update Posted: 2017-06-08
• Primary Completion: 2020-12
• Study Completion: 2020-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Patients with thrombosis and warfarin resistance

Exclusion Criteria

• less than 18 years

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	Genetic Mutations	Genetic Mutations
Warfarin resistant patients	Genetic Mutations	Genetic Mutations

Primary Outcome Measures

Name	Time	Method
number of patients with genetic polymorphism	6 months	patients with abnormal polymorphisms

Trial Locations

Locations (1)

Sherief Abd-Elsalam; 🇪🇬 Cairo, Tanta, Egypt